Certis Oncology

04/09/2026

One week until AACR 2026 — and we couldn't be more excited! 🙌

If you're heading to San Diego, make sure to stop by Booth #2403 to discover Certis Oncology Intelligence®!

Certis Oncology Intelligence® is an integrated platform that cross-references multi-modal datasets with foundational AI training data to surface hidden relationships within your institutional knowledge base — generating new hypotheses, translational insights, and opportunities to advance or reprioritize therapeutic programs. All within a single, continuously learning system.

🔓 Unlock legacy datasets.

⚙️ Test hypotheses in silico.

✅ Validate in relevant biological settings.

We're also presenting 3 posters across AI-driven combination therapy discovery, zero-shot therapeutic prediction, and tumor immunology — April 19, 20, and 21. Keep an eye out! 👀 https://hubs.la/Q04b1l7C0

Book a meeting with our team at the link below — we'd love to connect. 👇https://hubs.la/Q04b1xcR0

04/07/2026

Certis is proud to present 3️⃣ posters this year spanning AI-driven combination therapy discovery, agentic oncology intelligence, and tumor immunology. Here’s what to look out for:

🤖 Agentic AI in Cancer

📅 April 19 | 2–5 PM | Section 2, Poster #24

Certis Oncology Intelligence®: An Agentic AI Platform for Dynamic Preclinical Model Selection and Zero-Shot Therapeutic Prediction

→ Unlocking siloed data to generate new therapeutic insights

🧬 Immunomodulatory Effects of Targeted Therapies

📅 April 20 | 9 AM–12 PM | Section 45, Poster #2560

Radiotherapy Shapes Memory T Cell Dynamics and Region-Specific PD-1 Expression in the Glioblastoma Microenvironment

→ Insights into how radiotherapy reshapes immune dynamics in GBM

💊 Application of Bioinformatics to Cancer Biology

📅 April 21 | 2–5 PM | Section 1, Poster #5453

Machine Learning Accelerates Discovery of Synergistic PI3K–mTOR Combinations for Robust Tumor Growth Inhibition in KRAS G12 Mutant PDXs

→ ML-powered combination therapy discovery and in vivo validation

Coming to AACR? We'd love to connect! Stop by booth 2403 or reach out to set up time with our team. 👇

Link: https://hubs.la/Q049MQLr0

04/03/2026

We are proud to be recognized as a Webby Award Honoree in the 30th Annual Webby Awards — selected from nearly 13,000 entries and recognized by the International Academy of Digital Arts and Sciences (IADAS) as a leader in digital excellence!🏆

CertisOI Assistant™ is our agentic AI platform for biospecimen management, built to dynamically query biological and molecular datasets, unlock decades of siloed institutional knowledge, and rapidly test hypotheses in silico — putting the power of discovery and evaluation directly in researchers' hands.🔬💬

Discover how CertisOI Assistant is transforming preclinical exploration and accelerating oncology R&D⚡: https://hubs.la/Q049nhjv0

04/02/2026

AACR is two weeks away, and we are so excited to welcome the cancer research community to our hometown of San Diego!☀️

If you are heading to the annual meeting, come find us at Booth #2403. We're proud to be introducing Certis Oncology Intelligence® — an integrated platform that connects predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models into a single continuously learning system.

🔓Unlock legacy datasets.⚙️Test hypotheses in silico.✅ Validate in relevant biological settings.

Discover how the future of oncology intelligence can accelerate your preclinical pipeline. Book a meeting with our team: https://hubs.la/Q049nnML0

®

03/30/2026

Oncology drug development has a data problem — not a shortage of it, but a failure to translate it into reliable predictions of therapeutic response.

➡️Today, we're addressing that directly.

We're proud to introduce Certis Oncology Intelligence®, an integrated platform that connects predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models into a single, continuously learning system.

The platform integrates three layers:

🧠 CertisAI™ — zero-shot predictions of therapeutic response, even for novel compounds without prior experimental data

🧬 Agentic Biospecimen Management — dynamically query biological and molecular datasets, unlocking decades of siloed institutional knowledge and rapidly test hypotheses in silico

✅ Functional Biological Validation — experimental evidence from human-concordant cancer models that continuously refines predictive performance over time

The result: smarter decisions, stronger hypotheses, and a continuously improving foundation for oncology drug development.

Learn more about how we're redefining translational oncology:

Leverage predictive oncology intelligence with CertisAI™ for lead candidate selection, model selection, biomarker development, combinatorial strategies and more. Learn about artificial intelligence in cancer research.

02/23/2026

Does your platform have the brain power to crack GBM? 👊🧠

Last week at the GBM Drug Development Summit in Boston, our CTO Long Do took the stage to talk about what it actually takes to move a GBM program forward ➡️ smarter model selection, orthotopic study design aligned with the FDA Modernization Act, and predictive AI that accelerates biomarker-driven decisions.🚀

Missed us in Boston?
👉Access our event resources and learn more about our GBM platform: https://hubs.la/Q04435mL0

🤝Connect with us: https://hubs.la/Q04438pq0

02/17/2026

GBM drug development is evolving fast. Are your preclinical models keeping up?🧠👀

Tomorrow at 11:30 am at the GBM Summit in Boston, our CTO Long Do will present:

"Preclinical GBM Research in the Age of FDA Modernization and Predictive Artificial Intelligence"

He’ll cover:

🔬 Selecting clinically aligned, human-relevant GBM models
🐭Designing orthotopic intracranial studies aligned with the FDA Modernization Act
⚙️ Applying predictive AI and ML to accelerate biomarker-driven development

As regulatory guidance shifts and AI advances, smarter model selection is no longer optional; it's essential.

Get in touch and see how our team can accelerate your GBM pipeline: https://hubs.la/Q043h3m30

02/11/2026

Certis is excited to attend and present at the Glioblastoma Drug Development Summit! Join us Wednesday, Feb 18th at 11 AM to see how our clinically relevant GBM models support confident translational decision making 🧠

We specialize in orthotopic brain tumor models, managing studies end-to-end from in vitro proliferation to intracranial efficacy⚡🚀

What we bring to GBM development:
• 59 validated brain tumor PDX models
• Non-invasive MR imaging to confirm BBB pe*******on and tumor response
• Longitudinal tumor tracking and integrated radiation capabilities

📆 February 17-19th
📍The Royal Sonesta Boston

Curious how our preclinical GBM platform could strengthen your pipeline? 🤝👀Let's connect: https://hubs.la/Q042zcQ_0

02/04/2026

Last week in Tumor Models San Francisco, our presentation and conversations on the ground reinforced a clear takeaway: the success of next-gen modalities depends on choosing the right tumor model, supported by robust data and AI-driven insights.🔬⚡

We were grateful to engage alongside other presenters, whose perspectives and data helped shape thoughtful, candid conversations around complex biology, translational relevance, and AI-driven predictions in preclinical development.

Missed us in SF or want to explore how the right model and predictive insights can move your program forward?
🧠Learn more: https://hubs.la/Q041HPtj0
🤝Let's connect: https://hubs.la/Q041HLcV0

01/29/2026

Hot. Cold. Suppressive. Inflamed. GBM's immune landscape doesn't play by the rules—and your immuno-oncology strategy shouldn’t pretend that it does. 🧐🧠

Our I-O scientists bring deep expertise in GBM's complex immune environment, helping you navigate what others miss.

Humanized Model Capabilities
⭐Flexible HLA-matched or unmatched PBMCs
⭐Supports CAR-T, bispecific, and oncolytic virus testing
⭐Custom co-cultures across in vitro, ex vivo, and in vivo platforms

Advanced Profiling Tools
➡️Real-time immune–tumor imaging
➡️High-resolution immune profiling
➡️Comprehensive TME characterization

Learn more about how a powerful I-O platform can de-risk your GBM platform: https://hubs.la/Q040Q7480

Explore a strategic platform for leveraging patient-derived xenografts, humanized models, and predictive technologies to identify and optimize promising immunotherapeutic strategies.

01/26/2026

Karl the Fog can get a pass, but don’t let uncertainty cloud your preclinical pipeline. ☁️🌉

In just 2 days, join us at Tumor Models San Francisco to see how human-relevant tumor models and AI help teams sharpen translational insight while aligning with the FDA Modernization Act and reduced animal use. 🐭🔬

🎤 Featured Presentation
Preclinical Cancer Research in the Age of Reduced Animal Use and Artificial Intelligence
Speaker: Long Do, CTO, Certis Oncology

📅 Wednesday, January 28
⏰ 12:15 PM
📍Hyatt Centric Fisherman's Wharf

Connect with our team at Booth 2 or reserve a time to discuss how we can support your pipeline: https://hubs.la/Q040bj6L0

01/21/2026

Tourists love Lombard Street’s switchbacks. Your oncology pipeline deserves a faster route.

Join us at Tumor Models San Francisco to see how we help straighten the path from preclinical insight to clinical impact!

📅 Wednesday, January 28 – Thursday, January 29

📍 Hyatt Fisherman’s Wharf, 555 North Point St, San Francisco, CA 94133

Our team is excited to talk clinically relevant tumor models, AI driven efficacy predictions, and endpoints that drive confident decisions.

Visit us at Booth #2 or book a meeting with our team: https://hubs.la/Q03_CCjr0